For Physicians
Trelstar was the first intramuscular GnRH agonist indicated for the palliative treatment of advanced prostate cancer. Trelstar offers the unique combination of convenience, reliable suppression of testosterone and PSA levels, and injection site tolerability delivered via intramuscular administration. Trelstar is also the only GnRH agonist available in 1-, 3-, and 6-month formulations that is stored at room temperature; no refrigeration is required.
Trelstar.com contains important information for physicians who treat patients with advanced prostate cancer. Click the Trelstar Highlights link below to learn more about Trelstar’s testosterone suppression similar to levels achieved with surgical castration. You will find easy access to reimbursement and support programs, and our convenient online Trelstar ordering system. You also may find it helpful to visit the Administering Trelstar section for convenient instructions and to watch the Administering Trelstar Video.
Indication
Trelstar® is indicated for the palliative treatment of advanced prostate cancer.
Important Safety Information
The most commonly reported adverse events associated with the use of Trelstar® 22.5 mg included hot flushes (71.7%), erectile dysfunction (10.0%), and testicular atrophy (7.5%) • The most commonly reported adverse events associated with the use of Trelstar® 3.75 mg/Trelstar® 11.25 mg included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) • Trelstar® is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other GnRH agonists, or GnRH • Anaphylactic shock, hypersensitivity, and angioedema related to triptorelin administration have been reported • Trelstar® causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, urethral or bladder outlet obstruction, or spinal cord compression that may contribute to weakness or paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed. Hyperglycemia and an increased risk of developing diabetes, as well as increased risk of myocardial infarction, sudden cardiac death, and stroke have been reported in men receiving GnRH analogs. Patients should be monitored for blood glucose level and cardiovascular disease, and managed according to current clinical practice
MIXJECT® is a registered trademark of Medimop Medical Projects Ltd.
